Compare Amphastar Pharmaceuticals Inc (AMPH) vs Entegris Inc (ENTG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Entegris Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Entegris Inc trades at $139.03 (market cap $22.14B). The key difference: Entegris Inc is far larger — about 26.8× Amphastar Pharmaceuticals Inc's market cap, and Entegris Inc pays a 0.28% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | ENTG | |
|---|---|---|
Market Cap | $826.08M | $22.14B |
Sector | Health | Technology |
52-Week High | $30.81 | $184.00 |
52-Week Low | $16.87 | $68.80 |
Enterprise Value | $1.22B | $25.45B |
Dividend Yield | — | 0.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
ENTG trades at $145.35, down 0.51% today, with technical indicators showing a bearish trend and support at $143. The company reported Q1 2026 EPS of $0.86, beating estimates, but maintains premium valuations with a P/E of 84.02. Revenue has been stable around $3.2B annually, with net income margins improving to 8.18% in 2026. Analyst sentiment remains positive with a $178.40 price target, though recent news highlights volatility and valuation concerns.
Outlook: ENTG benefits from semiconductor industry tailwinds and AI-driven demand, but faces risks from high valuation and market volatility. The stock offers potential upside based on analyst targets, but investors should monitor earnings consistency and competitive pressures in the tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →
